Use of vasopeptidase inhibitors in the treatment of Metabolic Diseases, nephropathy and diseases associated with age

摘要

Use of vasopeptidase inhibitors of formula (i) for the prophylaxis and / or treatment of nephropathy in diabetic or non-diabetic patients, including nefroptia diabetic or non-diabetic glomerulonephritis, nephrotic syndrome, glomerular sclerosis, hypertensive nephrosclerosis, microalbumin Uria or end-stage renal disease.Or insulin resistance and Metabolic Disorders associated with Advanced Glycation End Products, such as diabetic complications, diabetic neuropathy, diabetic nephropathy, Diabetic Retinopathy, Cataracts, Myocardial Infarction and / or diabetic cardiomyopathy, or atherosclerosis Or endothelial dysfunction.